Anuncia Medical has announced the first successful implantation of its recently launched second-generation ReFlow Mini Flusher device for patients with hydrocephalus in the US.
The procedure has been conducted at Intermountain Primary Children’s Hospital in Salt Lake City by neurosurgeon Samuel Cheshier.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The patient in the procedure previously required 11 brain surgeries to address hydrocephalus, a chronic condition characterised by the accumulation of excessive cerebrospinal fluid (CSF) in the brain.
The device, which received approval from the US Food and Drug Administration (FDA), is intended for the treatment of patients with hydrocephalus or similar conditions.
Its reduced size and profile help better treat a wider range of hydrocephalus patients, spanning from infants to older adults.
When utilised alongside any shunt system brand, the ReFlow Mini Flusher facilitates the flushing of the patient’s CSF back into the ventricular catheter for maintaining, restoring or increasing hydrocephalus shunt flow.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAnuncia Medical sales and marketing new vice-president Mark Geiger said: “The ReFlow Mini Flusher developed off the ‘Gen 1’ platform, with a decade of work and recently published clinical data with four-plus years of follow-up, may profoundly impact hydrocephalus patients, by providing control and confidence, through noninvasive ventricular catheter flushing at home, to restore and maintain CSF flow.”
The first-generation ReFlow device has also been investigated in 11 clinical studies.
